Company: BDRX
Filing Date: 2025-11-24
Form Type: 424B3
Source: 0001214659-25-017136
Chunk: 11

Company: Biodexa Pharmaceuticals Plc
Filing Date: 2025-11-24
Form: 424B3
Chunk 11
---
rioritized in the three orphan brain cancer indications. Our development pipeline is as follows:

Corporate Information

We are a public limited company incorporated under the laws of England and Wales under registered number 09216368. Our principal executive offices are located at 1 Caspian Point, Caspian Way, Cardiff, CF10 4DQ, United Kingdom. The telephone number at our principal executive office is +44 29 2048 0180. Our service agent in the United States is located at Puglisi and Associates, 850 Library Avenue Newark, Delaware 19711. Our Depositary Shares, each representing 100,000 Ordinary Shares, are listed on the NASDAQ under the symbol “BDRX.”

Our corporate website is located at http://biodexapharma.com. The information contained on, or that can be accessed through, our website is not a part of this prospectus. We have included our website address in this prospectus solely as an inactive textual reference.

Additional Information

For additional information related to our business and operations, please refer to the reports incorporated herein by reference, including our Annual Report on Form 20-F for the year ended December 31, 2024, as filed with the SEC on April 11, 2025, and our Reports on Form 6-K, as filed with the SEC, as described in the section titled “Incorporation of Certain Information by Reference.”

| 7 |

The Offering

| Depositary Shares      
 offered by the Selling 
 Shareholders           |     | An aggregate of 109,800,00 Ordinary                                                                                                         
 Shares of the Company represented by 1,098 Depositary Shares, issuable upon the exercise of Series D Warrants. The selling shareholders     
 are identified in the table commencing on page 13.                                                                                          |
| Ordinary Shares        
 outstanding at         
 November 1, 2025       |     | 61,952,308,922 Ordinary                                                                                                                     
 Shares (including those represented by Depositary Shares)                                                                                   |
| Depositary Shares      |     | Each Depositary Share represents 100,000 Ordinary Shares.                                                                                   
 The depositary (through its custodian) will hold the Ordinary Shares underlying your                                                        
 Depositary Shares. You will have rights as provided in the deposit agreement among us, JPMorgan Chase Bank, N.A., as depositary, and all    
 owners and holders from time to time of Depositary Shares issued thereunder. You may, among other things,